Please use this identifier to cite or link to this item:
https://dora.health.qld.gov.au/qldresearchjspui/handle/1/372Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | McTaggart, S. | en |
| dc.contributor.author | Geoffrey Playford, E. | en |
| dc.contributor.author | Isbel, N. M. | en |
| dc.contributor.author | Snelling, P. | en |
| dc.contributor.author | Badve, S. V. | en |
| dc.contributor.author | Scaria, A. | en |
| dc.contributor.author | Beller, E. | en |
| dc.contributor.author | Cass, A. | en |
| dc.contributor.author | Zhang, L. | en |
| dc.contributor.author | De Zoysa, J. | en |
| dc.contributor.author | Vergara, L. A. | en |
| dc.contributor.author | Morrish, A. T. | en |
| dc.contributor.author | Clark, C. | en |
| dc.contributor.author | Pascoe, E. M. | en |
| dc.contributor.author | Johnson, D. W. | en |
| dc.contributor.author | Hawley, C. M. | en |
| dc.date.accessioned | 2018-06-16T20:32:49Z | - |
| dc.date.available | 2018-06-16T20:32:49Z | - |
| dc.date.issued | 2015 | en |
| dc.identifier.citation | 35, (7), 2015, p. 712-721 | en |
| dc.identifier.other | RIS | en |
| dc.identifier.uri | http://dora.health.qld.gov.au/qldresearchjspui/handle/1/372 | - |
| dc.description.abstract | Background: The HONEYPOT study recently reported that daily exit-site application of antibacterial honey was not superior to nasal mupirocin prophylaxis for preventing overall peritoneal dialysis (PD)-related infection. This paper reports a secondary outcome analysis of the HONEYPOT study with respect to exit-site infection (ESI) and peritonitis microbiology, infectious hospitalization and techniquefailure. Methods: A total of 371 PD patients were randomized to daily exit-site application of antibacterial honey plus usual exit-site care (N = 186) or intranasal mupirocin prophylaxis (in nasal Staphylococcus aureus carriers only) plus usual exit-site care (control, N = 185). Groups were compared on rates of organism-specific ESI and peritonitis, peritonitis-and infection-associated hospitalization, and technique failure (PD withdrawal). Results: The mean peritonitis rates in the honey and control groups were 0.41 (95% confidence interval [CI] 0.32-0.50) and 0.41 (95% CI 0.33-0.49) episodes per patient-year, respectively (incidence rate ratio [IRR] 1.01, 95% CI 0.75-1.35). When specific causative organisms were examined, no differences were observed between the groups for gram-positive (IRR 0.99, 95% CI 0.66-1.49), gram-negative (IRR 0.71, 95% CI 0.39-1.29), culture-negative (IRR 2.01, 95% CI 0.91-4.42), or polymicrobial peritonitis (IRR 1.08, 95% CI 0.36-3.20). Exit-site infection rates were 0.37 (95% CI 0.28-0.45) and 0.33 (95% CI 0.26-0.40) episodes per patient-year for the honey and control groups, respectively (IRR 1.12, 95% CI 0.81-1.53). No significant differences were observed between the groups for gram-positive (IRR 1.10, 95% CI 0.70-1.72), gram-negative (IRR: 0.85, 95% CI 0.46-1.58), culture-negative (IRR 1.88, 95% CI 0.67-5.29), or polymicrobial ESI (IRR 1.00, 95% CI 0.40-2.54). Times to first peritonitis-associated and first infection-associated hospitalization were similar in the honey and control groups. The rates of technique failure (PD withdrawal) due to PD-related infection were not significantly different between the groups. Conclusion: Compared with standard nasal mupirocin prophylaxis, daily topical exit-site application of antibacterial honey resulted in comparable rates of organism-specific peritonitis and ESI, infection-associated hospitalization, and infection-associated technique failure in PD patients.<br /> | en |
| dc.language | en | en |
| dc.relation.ispartof | Peritoneal Dialysis International | en |
| dc.title | The effect of exit-site antibacterial honey versus nasal mupirocin prophylaxis on the microbiology and outcomes of peritoneal dialysis-associated peritonitis and exit-site infections: A sub-study of the Honeypot trial | en |
| dc.type | Article | en |
| dc.subject.keywords | clinical trialconfidence interval | en |
| dc.subject.keywords | control group | en |
| dc.subject.keywords | controlled clinical trial | en |
| dc.subject.keywords | controlled study | en |
| dc.subject.keywords | disease carrier | en |
| dc.subject.keywords | honey | en |
| dc.subject.keywords | hospitalization | en |
| dc.subject.keywords | human | en |
| dc.subject.keywords | incidence | en |
| dc.subject.keywords | infection | en |
| dc.subject.keywords | infection rate | en |
| dc.subject.keywords | major clinical study | en |
| dc.subject.keywords | microbiology | en |
| dc.subject.keywords | peritoneal dialysis | en |
| dc.subject.keywords | peritonitis | en |
| dc.subject.keywords | prophylaxis | en |
| dc.subject.keywords | randomized controlled trial | en |
| dc.subject.keywords | Staphylococcus aureus | en |
| dc.subject.keywords | topical drug administration | en |
| dc.subject.keywords | antiinfective agent | en |
| dc.subject.keywords | pseudomonic acid | en |
| dc.relation.url | http://linksource.ebsco.com/ls.b6e6cc08-c492-42af-aec4-c6084e18e68c.true/linking.aspx?sid=EMBASE&issn=17184304&id=doi:10.3747%2Fpdi.2014.00206&atitle=The+effect+of+exit-site+antibacterial+honey+versus+nasal+mupirocin+prophylaxis+on+the+microbiology+and+outcomes+of+peritoneal+dialysis-associated+peritonitis+and+exit-site+infections%3A+A+sub-study+of+the+Honeypot+trial&stitle=Peritoneal+Dial.+Int.&title=Peritoneal+Dialysis+International&volume=35&issue=7&spage=712&epage=721&aulast=&aufirst=&auinit=&aufull=+&coden=PDIIE&isbn=&pages=712-721&date=2015&auinit1=&auinitm= | en |
| dc.relation.url | http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L607393225http://dx.doi.org/10.3747/pdi.2014.00206 | en |
| dc.identifier.risid | 635 | en |
| dc.description.pages | 712-721 | en |
| item.grantfulltext | none | - |
| item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
| item.openairetype | Article | - |
| item.fulltext | No Fulltext | - |
| item.cerifentitytype | Publications | - |
| Appears in Sites: | Queensland Health Publications Sunshine Coast HHS Publications | |
Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.